Oct 2026· European Heart Journal· Vol 47· 0 citations
TL;DR
Subgroup findings suggest differential benefits according to ventricular function and renal status, supporting early SGLT2 inhibitor use in acute heart failure.
Abstract
Acute heart failure (AHF) remains a major cause of morbidity and mortality worldwide, with persistently high in-hospital death rates despite advances in guideline-directed therapy (1).
Sodium–glucose cotransporter-2 (SGLT2) inhibitors have demonstrated rapid hemodynamic and renal benefits across the spectrum of left ventricular ejection fraction (2). Although both dapagliflozin and empagliflozin have proven efficacy in heart failure, direct comparative data, particularly when initiated early during cardiac ICU admission, remain limited (3).
To compare early in-hospital initiation of dapagliflozin versus empagliflozin in patients admitted for acute heart failure and evaluate their impact on in-hospital survival and safety.
We conducted a retrospective cohort study of 1,800 consecutive adults admitted to the cardiac ICU for acute heart failure (de novo or acute decompensation) between July 2023 and April 2025. Early initiation of SGLT2 inhibitors was defined as treatment within 48 hours of admission. After applying exclusion criteria, including dialysis, prior transplantation, eGFR <30 mL/min/1.73 m², cardiogenic shock, diabetic ketoacidosis, symptomatic hypotension, or early transfer, 1,546 patients were included. Patients were categorised into dapagliflozin (n=450), empagliflozin (n=398), or no early SGLT2 inhibitor groups. The primary endpoint was all-cause in-hospital mortality. Multivariable logistic regression assessed independent associations with mortality.
Among 1,546 included patients (mean age 63.4 ± 15.1 years; 57.5% male; mean LVEF 44.4 ± 14.6%), early SGLT2 inhibitors were initiated in 848 patients. Overall, in-hospital survival did not differ significantly between dapagliflozin and empagliflozin (P=0.29). Subgroup analyses showed higher survival with dapagliflozin in patients with reduced LVEF (76% vs 61%; P=0.001), whereas empagliflozin was associated with higher survival in patients with right ventricular dysfunction (36.8% vs 11.8%; P=0.02) and chronic kidney disease (33.3% vs 25%; P=0.032). Hypotension was rare (0% empagliflozin vs 0.5% dapagliflozin; P<0.001), and rates of acute kidney injury were similar between groups. Low event rates were observed in patients receiving combined SGLT2 inhibitor and sacubitril/valsartan therapy.
Early initiation of dapagliflozin and empagliflozin was associated with comparable overall survival and favourable safety profiles. Subgroup findings suggest differential benefits according to ventricular function and renal status, supporting early SGLT2 inhibitor use in acute heart failure.
Abstract Background and Aims Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are a foundational therapy for heart failure (HF), yet initiation is frequently delayed in clinical practice. Data comparing outcomes associated with early versus delayed or no initiation of SGLT2is following hospitalization for heart fail...
Stephen J. Greene, G. Tskhvarashvili, P. Tran et al.· ESC Heart Failure· 0 citations
Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular death and heart failure (HF) events across the whole spectrum of ejection fraction, and their benefit emerges within weeks of the first dose. This has moved the clinical question from whether to use them to when to start them. Hospitalization for a...
Chelsya Rafaela Brito Santiago, Cauan José Finato, Alaíze Nonato da Silva et al.· International Health Science...· 0 citations
Highlights What are the main findings? Early dapagliflozin initiation significantly reduced all-cause mortality but not heart failure hospitalization in the all-population analysis. Initiation of dapagliflozin was associated with a significant reduction in urinary tract infections (UTIs), without an increase in any adv...
Abdullah Almaqhawi, Ahmed K. Alsaif, Hamza Ashraf et al.· Biomedicines· 0 citations
Acute heart failure (HF) patients are at high risk, especially in the first three months following discharge, when rehospitalizations are 30% common and mortality can be close to 10%. Although sodium-glucose cotransporter-2 (SGLT2) inhibitors are essential for treating heart failure, their benefit when initiated...
N. Shafi, F. Khalid, M. Elshabrawi et al.· European Heart Journal· 0 citations
In this prospective observational cohort of Pakistani adults with HFpEF, empagliflozin 10 mg once daily added to standard heart failure therapy was associated with a significantly lower hazard of first HF hospitalization, slower deterioration in renal function, and greater improvement in health-related quality of life...
Raffat Sultana, N. Sultana, S. Jaffery et al.· Pakistan Heart Journal· 0 citations
The efficacy of sodium–glucose cotransporter 2 inhibitors in heart failure (HF) has been well established. Dapagliflozin 10 mg has been shown to improve clinical outcomes in HF in DAPA-HF and DELIVER; however, evidence supporting low-dose dapagliflozin in HF remains limited.
This post hoc analysis of the D...
S. Ito, F. Yoshihara, M. Imazu et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.